STAT News

STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug

Life Biosciences said yesterday that three glaucoma patients have now received a single injection of its experimental cellular reprogramming drug, with no serious adverse events.

By STAT News

1 min read
STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights